- Home
- WNW vs GLTO Comparison
WNW vs GLTO Comparison
Compare WNW & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNW
- GLTO
- Stock Information
- Founded
- WNW 2015
- GLTO 2011
- Country
- WNW China
- GLTO Denmark
- Employees
- WNW N/A
- GLTO N/A
- Industry
- WNW Catalog/Specialty Distribution
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- WNW Consumer Discretionary
- GLTO Health Care
- Exchange
- WNW Nasdaq
- GLTO Nasdaq
- Market Cap
- WNW 5.4M
- GLTO 4.5M
- IPO Year
- WNW 2020
- GLTO 2020
- Fundamental
- Price
- WNW $1.88
- GLTO $2.81
- Analyst Decision
- WNW
- GLTO Buy
- Analyst Count
- WNW 0
- GLTO 1
- Target Price
- WNW N/A
- GLTO $10.00
- AVG Volume (30 Days)
- WNW 108.6K
- GLTO 251.4K
- Earning Date
- WNW 11-14-2025
- GLTO 10-31-2025
- Dividend Yield
- WNW N/A
- GLTO N/A
- EPS Growth
- WNW N/A
- GLTO N/A
- EPS
- WNW 9.06
- GLTO N/A
- Revenue
- WNW $158,485.00
- GLTO N/A
- Revenue This Year
- WNW N/A
- GLTO N/A
- Revenue Next Year
- WNW N/A
- GLTO N/A
- P/E Ratio
- WNW $0.23
- GLTO N/A
- Revenue Growth
- WNW N/A
- GLTO N/A
- 52 Week Low
- WNW $0.95
- GLTO $2.01
- 52 Week High
- WNW $70.00
- GLTO $14.56
- Technical
- Relative Strength Index (RSI)
- WNW 46.97
- GLTO 40.40
- Support Level
- WNW $2.00
- GLTO $2.53
- Resistance Level
- WNW $2.29
- GLTO $2.99
- Average True Range (ATR)
- WNW 0.38
- GLTO 0.32
- MACD
- WNW -0.01
- GLTO -0.01
- Stochastic Oscillator
- WNW 10.88
- GLTO 22.73
About WNW Meiwu Technology Company Limited
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.